Siga Technologie Stock Price, News & Analysis

SIGA Technologies (NASDAQ: SIGA) has entered into an exclusive license agreement with Vanderbilt University for a portfolio of preclinical fully human monoclonal antibodies (mAbs). These mAbs have potential as treatments for a broad range of orthopoxviruses, including smallpox and mpox. The agreement grants SIGA exclusive rights to develop, manufacture, and commercialize these mAbs globally.

The mAbs, developed by Dr. James Crowe at Vanderbilt University Medical Center, have shown promise in preclinical models and could be used as standalone treatments or in combination with SIGA's TPOXX® franchise. The U.S. Department of Defense is currently funding the development of these mAbs through Phase 1 clinical trials. SIGA aims to leverage its expertise in orthopoxvirus and partnerships with U.S. Government agencies to maximize the impact of these potential new therapies.

SIGA Technologies, Inc. (NASDAQ: SIGA) has announced an agreement to supply TPOXX® (tecovirimat) in Morocco. This marks SIGA's first commercial sale of TPOXX in Africa. The contract was executed in response to a request from Morocco's Ministry of Health to prepare and protect citizens against potential mpox outbreaks.

Tecovirimat is already approved in the U.S., Canada, and the EU, and has been available in Africa through clinical trials and WHO's emergency use access protocol. SIGA's Vice President of International Markets, Victor Gomes, expressed pride in providing access to this antiviral therapy in Morocco and thanked the Ministry of Health for their collaboration in ensuring quick delivery.

SIGA Technologies (NASDAQ: SIGA) has secured a new $9 million contract with the U.S. Department of Defense for the procurement of TPOXX®, an antiviral medication. This marks the third DOD contract in three years for SIGA. The order primarily consists of oral TPOXX®, with a small amount of intravenous formulation included.

SIGA is also collaborating with the DOD's JPEO-CBRND on developing a Post-exposure Prophylaxis (PEP) indication for oral TPOXX®, supported by a $27 million development contract. With this new award, SIGA now has approximately $154 million in outstanding TPOXX® orders, with over 85% generated in the past three months.

SIGA Technologies announced topline results from the PALM 007 clinical trial of tecovirimat for mpox treatment. The study did not meet its primary endpoint of statistically significant improvement in lesion resolution time. However, meaningful improvements were observed in patients treated early (within 7 days of symptom onset) and those with severe disease (100+ skin lesions). Tecovirimat demonstrated a safety profile comparable to placebo. Despite missing the primary endpoint, SIGA remains encouraged by the potential benefits for specific patient groups. The company plans to analyze the data further and continue additional clinical trials to evaluate tecovirimat's efficacy in real-world settings.

SIGA Technologies (NASDAQ: SIGA) reported financial results for Q2 and H1 2024. Key highlights include:

- Q2 product sales of $20.7 million, including $18 million of IV TPOXX sales to the U.S. Government

- H1 product revenues of $44.6 million from diverse TPOXX deliveries

- Q2 net income of $1.8 million ($0.03 per diluted share)

- H1 net income of $12.1 million ($0.17 per diluted share)

- Received a $113 million procurement order for oral TPOXX from the U.S. Government in July

- Expanded international presence with new customers in ASEAN and Asia Pacific regions

- Special cash dividend of $0.60 per share paid in April

SIGA Technologies, Inc. (NASDAQ: SIGA), a commercial-stage pharmaceutical company, has announced a webcast and conference call scheduled for August 1, 2024, at 4:30 P.M. ET. The purpose of this event is to provide a business update following the release of the company's second-quarter 2024 financial results. CEO Diem Nguyen and CFO Daniel Luckshire will be participating in the call.

Investors and interested parties can access the live webcast on SIGA's website or dial in using the provided numbers. A replay of the call will be available for two weeks, and the archived webcast will be accessible in the Investor Relations section of the company's website.

SIGA Technologies (NASDAQ: SIGA) has announced a significant $113 million procurement order from the U.S. Department of Health and Human Services for oral TPOXX® treatment courses. This order, exercised under a current contract, aims to enhance orthopoxvirus preparedness. CEO Diem Nguyen highlighted that this order builds upon previous orders from the U.S. government and 15 international customers in 2023, supporting consistent action for public health protection against natural, accidental, or intentional threats. The project is supported by federal funds from various U.S. health agencies, including BARDA and the Strategic National Stockpile.

SIGA Technologies has announced an agreement to sell its antiviral drug TPOXX (tecovirimat) to ASEAN member states. The agreement was signed by the Ministry of Health of Brunei Darussalam on behalf of ASEAN, reflecting a collective effort to prepare for public health events such as Mpox and smallpox. This collaboration with Meridian Medical Technologies aims to ensure an adequate supply of TPOXX in the region, which comprises over 600 million people with a GDP of $3.6 trillion. Financial details of the agreement were not disclosed.

Calidi Biotherapeutics has partnered with SIGA Technologies to advance its RTNova virotherapy for lung cancer and metastatic solid tumors. RTNova leverages a vaccinia virus enveloped by a human cell membrane to evade immunity and enhance therapeutic functions. SIGA will supply TPOXX, an antiviral agent against vaccinia virus, to support RTNova's development. This collaboration aims to create a universal treatment for all tumor types and will initially focus on lung cancer and metastatic solid tumors. RTNova's novel approach allows for easy administration and a broader patient reach. The partnership offers a safety mechanism for clinical trials, ensuring better regulatory compliance and patient safety.